These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: RTHLVFFARK-NH2: A potent and selective modulator on Cu2+-mediated amyloid-β protein aggregation and cytotoxicity.
    Author: Meng J, Zhang H, Dong X, Liu F, Sun Y.
    Journal: J Inorg Biochem; 2018 Apr; 181():56-64. PubMed ID: 29407908.
    Abstract:
    Dysfunctional accumulation of amyloid-β (Aβ) protein stimulated by Cu2+ is considered as a key process in the pathogenesis of Alzheimer's disease (AD). Thus, bifunctional substances capable of chelating Cu2+ and inhibiting Aβ aggregation are promising therapeutic agents against AD. Herein, a novel bifunctional decapeptide RTHLVFFARK-NH2 (RK10) was developed by integrating a metal chelating tripeptide (RTH) and an Aβ aggregation inhibitor Ac-LVFFARK-NH2 (LK7). The high selectivity of RK10 for Cu2+ over other biologically relevant metal ions was demonstrated by isothermal titration calorimetry. RK10 bound Cu2+ with a dissociation constant of 0.02 μM. This enabled RK10 to sequester Cu2+ from Aβ40-Cu2+ species and to arrest the production of reactive oxygen species (ROS) catalyzed by Cu2+ or Aβ40-Cu2+ species. Extensive physical, biophysical and biological studies indicate that RK10 targeted free and Cu2+-bound Aβ40 species, suppressed Aβ40 aggregation, and diminished the cytotoxicity induced by Aβ40 and Cu2+-mediated Aβ40 in cultured SH-SY5Y cells. Taken together, the results proved the excellent selective roles of RK10 in inhibiting Cu2+-mediated Aβ40 aggregation and eliminating ROS generation catalyzed by Cu2+/Aβ40-Cu2+ species. Thus, this work provided new insight into the design and development of potent bifunctional inhibitors against Aβ aggregation and cytotoxicity.
    [Abstract] [Full Text] [Related] [New Search]